By Dean Seal
Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients.
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, the company said Tuesday.
The approval makes Ozempic the most broadly indicated GLP-1 drug on the market, the Bagsvaerd, Denmark, company said. The FDA approved semaglutide for weight loss under the brand name Wegovy in 2021.
The European Union's drug regulator has already thrown its support behind a label expansion for Ozempic to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes. The European Medicines Agency's backing came after a 2024 trial showed Ozempic cutting the risk of kidney disease-related events in diabetic patients by 24%.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 28, 2025 15:06 ET (20:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.